Publications by authors named "Robbert J van Alphen"

Claim this Profile
T
The role of adjuvant chemotherapy in rectal cancer: A nationwide cohort study from the Netherlands.
Aaya Darai, Tijmen Koëter, Felice N van Erning, Robbert J van Alphen, Henk M W Verheul

Colorectal Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial.
Marinde J G Bond, Karen Bolhuis, Olaf J L Loosveld, Jan Willem B de Groot, Helga Droogendijk, Robbert J van Alphen

JAMA Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study.
Niels A D Guchelaar, Stefan A J Buck, Leni van Doorn, Koen G A M Hussaarts, Yorick Sandberg, Robbert J van Alphen

Clin Pharmacokinet· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
Marinde J G Bond, Karen Bolhuis, Olaf J L Loosveld, Jan Willem B de Groot, Helga Droogendijk, Robbert J van Alphen

Lancet Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.
C Louwrens Braal, Agnes Jager, Esther Oomen-de Hoop, Justin D Westenberg, Koen M W T Lommen, Robbert J van Alphen

Clin Pharmacokinet· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).
Annelot G J van Rossum, Ingrid A M Mandjes, Erik van Werkhoven, Harm van Tinteren, A Elise van Leeuwen-Stok, Robbert J van Alphen

Breast Care (Basel)· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Koen G A M Hussaarts, Florine A Berger, Lisette Binkhorst, Esther Oomen-de Hoop, Roelof W F van Leeuwen, Robbert J van Alphen

Pharm Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.
Johannes J M Kwakman, Erik van Werkhoven, Lieke H J Simkens, Johan M van Rooijen, Yes A J van de Wouw, Robbert J van Alphen

Clin Colorectal Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study.
Bodine P S Belderbos, Koen G A M Hussaarts, Leonie J van Harten, Esther Oomen-de Hoop, Peter de Bruijn, Robbert J van Alphen

Br J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen.
Koen G A M Hussaarts, Daan P Hurkmans, Esther Oomen-de Hoop, Leonie J van Harten, Stan Berghuis, Robbert J van Alphen

Cancers (Basel)· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.
Bodine P S Belderbos, Ronald de Wit, Esther Oomen-de Hoop, Annemieke Nieuweboer, Paul Hamberg, Robbert J van Alphen

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.
Annemieke J M Nieuweboer, Anne-Joy M de Graan, Paul Hamberg, Sander Bins, Robert J van Soest, Robbert J van Alphen

Clin Cancer Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.
Lisette Binkhorst, Marjolein Bannink, Peter de Bruijn, Jan Ruit, Helga Droogendijk, Robbert J van Alphen

Clin Pharmacokinet· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.
Lisette Binkhorst, Jacqueline S L Kloth, Annelieke S de Wit, Peter de Bruijn, Mei H Lam, Robbert J van Alphen

Breast Cancer Res Treat· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Anne-Joy M de Graan, Sebastiaan F Teunissen, Filip Y F L de Vos, Walter J Loos, Ron H N van Schaik, Robbert J van Alphen

J Clin Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial design for cancer (cell)-specific anticancer therapies.
Robbert J van Alphen, J Verweij, F A L M Eskens

Expert Opin Ther Targets· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis